Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Soticlestat, a novel cholesterol 24-hydroxylase inhibitor shows a therapeutic potential for neural hyperexcitation in mice
Toshiya Nishi, Shinichi Kondo, Maki Miyamoto, et al.
Scientific Reports (2020) Vol. 10, Iss. 1
Open Access | Times Cited: 64

Showing 26-50 of 64 citing articles:

Synthetic Strategies and SAR Studies of Triazine‐Based Antiepileptic Agents: A Bench to Bedside Approach
Nisha Vats, Asiya Parveen, Mohd Shafeeque, et al.
Archiv der Pharmazie (2025) Vol. 358, Iss. 5
Closed Access
Structure-Based Design of a Novel Series of Cholesterol 24-Hydroxylase (Ch24h) Inhibitors Bearing 1,3-Oxazole as a Heme-Iron Binding Group
Y. ITO, Tomoaki Hasui, Eiji Kimura, et al.
(2025)
Closed Access
Pharmacokinetics, pharmacodynamics and safety assessment of multiple doses of soticlestat in healthy volunteers
Shining Wang, Grace Chen, Emilio Merlo Pich, et al.
British Journal of Clinical Pharmacology (2022) Vol. 88, Iss. 6, pp. 2899-2908
Open Access | Times Cited: 16
Population pharmacokinetics, enzyme occupancy, and pharmacodynamic modeling of soticlestat in patients with developmental and epileptic encephalopathies
Wei Yin, Axel Facius, Mahnaz Asgharnejad, et al.
Clinical and Translational Science (2024) Vol. 17, Iss. 3
Open Access | Times Cited: 3
Innovative drug discovery strategies in epilepsy: integrating next-generation syndrome-specific mouse models to address pharmacoresistance and epileptogenesis
Melissa Barker‐Haliski, Nicole A. Hawkins
Expert Opinion on Drug Discovery (2024) Vol. 19, Iss. 9, pp. 1099-1113
Closed Access | Times Cited: 3
Precision Medicine Approaches for Infantile-Onset Developmental and Epileptic Encephalopathies
Kenneth A. Myers, Ingrid E. Scheffer
The Annual Review of Pharmacology and Toxicology (2021) Vol. 62, Iss. 1, pp. 641-662
Closed Access | Times Cited: 19
Cholesterol 24-hydroxylase is a novel pharmacological target for anti-ictogenic and disease modification effects in epilepsy
Alessia Salamone, Gaetano Terrone, Rossella Di Sapia, et al.
Neurobiology of Disease (2022) Vol. 173, pp. 105835-105835
Open Access | Times Cited: 13
Cannabidiol reveals a disruptive strategy for 21st century epilepsy drug discovery
Aarón del Pozo, Melissa Barker‐Haliski
Experimental Neurology (2022) Vol. 360, pp. 114288-114288
Open Access | Times Cited: 13
From diagnosis to treatment in genetic epilepsies: Implementation of precision medicine in real-world clinical practice
Matthias De Wachter, An‐Sofie Schoonjans, Sarah Weckhuysen, et al.
European Journal of Paediatric Neurology (2023) Vol. 48, pp. 46-60
Closed Access | Times Cited: 8
Targeted Molecular Strategies for Genetic Neurodevelopmental Disorders: Emerging Lessons from Dravet Syndrome
Robert Lersch, Rawan Jannadi, Leonie Grosse, et al.
The Neuroscientist (2022) Vol. 29, Iss. 6, pp. 732-750
Open Access | Times Cited: 12
Brain-Specific Oxysterols and Risk of Schizophrenia in Clinical High-Risk Subjects and Patients With Schizophrenia
Zuoli Sun, Lei Zhao, Qijing Bo, et al.
Frontiers in Psychiatry (2021) Vol. 12
Open Access | Times Cited: 15
Targeting cytochrome P450 46A1 and brain cholesterol 24-hydroxylation to treat neurodegenerative diseases
Irina A. Pikuleva
Exploration of Neuroprotective Therapy (2021)
Open Access | Times Cited: 15
Discovery of Novel 3-Piperidinyl Pyridine Derivatives as Highly Potent and Selective Cholesterol 24-Hydroxylase (CH24H) Inhibitors
Y. Kajita, Shuhei Ikeda, Masato Yoshikawa, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 4, pp. 3343-3358
Closed Access | Times Cited: 11
Soticlestat, a novel cholesterol 24-hydroxylase inhibitor, modifies acute seizure burden and chronic epilepsy-related behavioral deficits following Theiler's virus infection in mice
Melissa Barker‐Haliski, Toshiya Nishi, H. Steve White
Neuropharmacology (2022) Vol. 222, pp. 109310-109310
Open Access | Times Cited: 11
Current and emerging pharmacotherapy for the treatment of Lennox-Gastaut syndrome
Frank Besag, Michael J. Vasey, Richard Chin
Expert Opinion on Pharmacotherapy (2023) Vol. 24, Iss. 11, pp. 1249-1268
Open Access | Times Cited: 6
Lennox-Gastaut Syndrome: Current Treatments, Novel Therapeutics, and Future Directions
Julie A. Nelson, Kelly G. Knupp
Neurotherapeutics (2023) Vol. 20, Iss. 5, pp. 1255-1262
Open Access | Times Cited: 6
Investigation of the absolute bioavailability, mass balance, metabolism, and excretion of the cholesterol 24‐hydroxylase inhibitor soticlestat in healthy volunteers
Wei Yin, T. Eric Ballard, Xiaochun Zhu, et al.
British Journal of Clinical Pharmacology (2023) Vol. 90, Iss. 2, pp. 516-527
Open Access | Times Cited: 6
Phase 1 pharmacokinetic and safety study of soticlestat in participants with mild or moderate hepatic impairment or normal hepatic function
Wei Yin, P. P. Mitra, Veronique Copalu, et al.
Pharmacology Research & Perspectives (2024) Vol. 12, Iss. 4
Open Access | Times Cited: 2
Cholesterol in Brain Development and Perinatal Brain Injury: More than a Building Block
Fuxin Lu, Donna M. Ferriero, Xiangning Jiang
Current Neuropharmacology (2021) Vol. 20, Iss. 7, pp. 1400-1412
Open Access | Times Cited: 14
Population pharmacokinetics, enzyme occupancy, and 24S‐hydroxycholesterol modeling of soticlestat, a novel cholesterol 24‐hydroxylase inhibitor, in healthy adults
Wei Yin, Axel Facius, Thomas Wagner, et al.
Clinical and Translational Science (2023) Vol. 16, Iss. 7, pp. 1149-1162
Open Access | Times Cited: 5
Oxysterols in Central and Peripheral Synaptic Communication
Alexey M. Petrov
Advances in experimental medicine and biology (2023), pp. 91-123
Closed Access | Times Cited: 5
Brain Acetyl-CoA Production and Phosphorylation of Cytoskeletal Proteins Are Targets of CYP46A1 Activity Modulation and Altered Sterol Flux
Natalia Mast, Alexey M. Petrov, Erin Prendergast, et al.
Neurotherapeutics (2021) Vol. 18, Iss. 3, pp. 2040-2060
Open Access | Times Cited: 12
Preclinical characterization of [18F]T-008, a novel PET imaging radioligand for cholesterol 24-hydroxylase
Tatsuki Koike, Cristian Constantinescu, Shuhei Ikeda, et al.
European Journal of Nuclear Medicine and Molecular Imaging (2021) Vol. 49, Iss. 4, pp. 1148-1156
Open Access | Times Cited: 12
Current and promising therapeutic options for Dravet syndrome
Antonella Riva, Gianluca D’Onofrio, Elisabetta Amadori, et al.
Expert Opinion on Pharmacotherapy (2022) Vol. 23, Iss. 15, pp. 1727-1736
Closed Access | Times Cited: 9
Characterization of soticlestat, a novel cholesterol 24-hydroxylase inhibitor, in acute and chronic neurodegeneration models
Shigeo Hasegawa, Sayuri Watanabe, Shinji Fujimoto, et al.
Neuroscience Research (2024)
Open Access | Times Cited: 1

Scroll to top